4376 - 4400 of 7939 Results
Title
Year
- CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers2020OPENTitle: CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriersJournal Name: Translational NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s40035-020-00192-4Best OA location URL: https://translationalneurodegeneration.biomedcentral.com/track/pdf/10.1186/s40035-020-00192-4Citation Count: 37
- Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease2020OPENTitle: Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson DiseaseJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2020.00370Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2020.00370/pdfCitation Count: 9
-
OPENTitle: Revised Self-Monitoring ScaleJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 22Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000009451Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357291Citation Count: 27
-
OPENTitle: Health-Related Quality of Life Outcomes from Botulinum Toxin Treatment in SpasticityJournal Name: ToxinsPublisher: MDPI AGVol: 12Issue #: 5Start Page: 292End Page: 292Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/toxins12050292Best OA location URL: https://www.mdpi.com/2072-6651/12/5/292/pdf?version=1590147891Citation Count: 7
- The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?2020RESTRICTEDTitle: The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?Journal Name: Expert Opinion on Therapeutic TargetsPublisher: Informa UK LimitedVol: 24Issue #: 7Start Page: 679End Page: 693Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14728222.2020.1758668Citation Count: 14
- Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice2020RESTRICTEDTitle: Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practiceJournal Name: Expert Review of NeurotherapeuticsPublisher: Informa UK LimitedVol: 20Issue #: 5Start Page: 477End Page: 495Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14737175.2020.1752669Citation Count: 29
-
OPENTitle: Serum triglycerides in Alzheimer diseaseJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 94Issue #: 20Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0000000000009436Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526673Citation Count: 70
- A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation2020RESTRICTEDTitle: A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst StimulationJournal Name: Movement DisordersPublisher: WileyVol: 35Issue #: 8Start Page: 1471End Page: 1475Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28083Citation Count: 21
-
OPENTitle: All that’s fit to preprintJournal Name: Nature BiotechnologyPublisher: Springer Science and Business Media LLCVol: 38Issue #: 5Start Page: 507End Page: 507Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41587-020-0536-xBest OA location URL: https://www.nature.com/articles/s41587-020-0536-x.pdfCitation Count: 10
- Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate2020OPENTitle: Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidateJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 138Issue #:Start Page: 104789End Page: 104789Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2020.104789Best OA location URL: https://doi.org/10.1016/j.nbd.2020.104789Citation Count: 25
-
RESTRICTEDTitle: An Overview of the Current State and the Future of Ataxia TreatmentsJournal Name: Neurologic ClinicsPublisher: Elsevier BVVol: 38Issue #: 2Start Page: 449End Page: 467Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.ncl.2020.01.008Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220524Citation Count: 13
-
RESTRICTEDTitle: Corneal confocal microscopy: ready for prime timeJournal Name: Clinical and Experimental OptometryPublisher: Informa UK LimitedVol: 103Issue #: 3Start Page: 265End Page: 277Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/cxo.12887Citation Count: 77
- Cortical Thickness, Neurocognition and Social Cognition in Euthymic Individuals With Bipolar Disorder and Their Healthy Siblings2020RESTRICTEDTitle: Cortical Thickness, Neurocognition and Social Cognition in Euthymic Individuals With Bipolar Disorder and Their Healthy SiblingsJournal Name: Biological PsychiatryPublisher: Elsevier BVVol: 87Issue #: 9Start Page: S378End Page: S378Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.biopsych.2020.02.967Citation Count: 0
- Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression2020RESTRICTEDTitle: Creation of a gene expression classifier for predicting Parkinson’s disease rate of progressionJournal Name: Journal of Neural TransmissionPublisher: Springer Science and Business Media LLCVol: 127Issue #: 5Start Page: 755End Page: 762Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00702-020-02194-yCitation Count: 7
- Cross-Platform Comparison of Immunoassay Technologies to Assess Cytokine Markers in Patients With Post-Traumatic Stress Disorder and Parkinson’s Disease2020RESTRICTEDTitle: Cross-Platform Comparison of Immunoassay Technologies to Assess Cytokine Markers in Patients With Post-Traumatic Stress Disorder and Parkinson’s DiseaseJournal Name: Biological PsychiatryPublisher: Elsevier BVVol: 87Issue #: 9Start Page: S378End Page: S378Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.biopsych.2020.02.968Citation Count: 0
-
RESTRICTEDTitle: Deciphering DDX3X Syndrome to Capture Determinants of Intellectual DisabilityJournal Name: Biological PsychiatryPublisher: Elsevier BVVol: 87Issue #: 9Start Page: S378End Page: S379Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.biopsych.2020.02.969Citation Count: 0
-
OPENTitle: ePresentation SessionsJournal Name: European Journal of NeurologyPublisher: WileyVol: 27Issue #: S1Start Page: 103End Page: 522Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1111/ene.14307Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14307Citation Count: 5
-
RESTRICTEDTitle: Expert comment: “A case of missing pathology in a patient with LRRK2 Parkinson's disease”Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 74Issue #:Start Page: 78End Page: 79Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.11.005Citation Count: 3
-
OPENTitle: How Do I Examine Patients With Functional Tremor?Journal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 5Start Page: 587End Page: 587Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12966Best OA location URL: https://movementdisorders.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12966Citation Count: 6
-
RESTRICTEDTitle: Initiation of pharmacological therapy in Parkinson's disease: when, why, and howJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 5Start Page: 452End Page: 461Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30036-3Citation Count: 121
- Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson Disease2020OPENTitle: Kinesthetic Cells within the Subthalamic Nucleus and Deep Brain Stimulation for Parkinson DiseaseJournal Name: World NeurosurgeryPublisher: Elsevier BVVol: 139Issue #:Start Page: e784End Page: e791Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.wneu.2020.04.160Best OA location URL: http://manuscript.elsevier.com/S187887502030869X/pdf/S187887502030869X.pdfCitation Count: 2
-
RESTRICTEDTitle: Long-term unsupervised mobility assessment in movement disordersJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 19Issue #: 5Start Page: 462End Page: 470Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(19)30397-7Best OA location URL: https://pure.rug.nl/ws/files/121196279/Long_term_unsupervised_mobility_assessment_in.pdfCitation Count: 187
-
OPENTitle: Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of ParkinsonismJournal Name: Movement DisordersPublisher: WileyVol: 35Issue #: 8Start Page: 1388End Page: 1395Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28060Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316785Citation Count: 20
- Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 Experience2020RESTRICTEDTitle: Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID‐19 ExperienceJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 4Start Page: 361End Page: 372Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12965Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12965Citation Count: 93
-
RESTRICTEDTitle: Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic reviewJournal Name: Complementary Therapies in Clinical PracticePublisher: Elsevier BVVol: 39Issue #:Start Page: 101154End Page: 101154Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.ctcp.2020.101154Citation Count: 17